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Objective: The study aimed to investigate correlates of cognition among patients with schizophrenia.
Methods: Over a three month period, in-patients diagnosed with schizophrenia (n = 50) and mood disorders
(n = 50) were recruited into the study. Both groups of patients were assessed using the Schedules for Clinical
Assessment in Neuropsychiatry (SCAN), the Annett Hand Preference Questionnaire (AHPQ) and the Global
Assessment of Function Scale (GAF). Patients with schizophrenia were further assessed using the Positive and
Negative Syndromes Scale, PANSS and the Clinical Global impression (CGI). The cognitive screen section of
SCAN (comprising Verbal Trails Test and Mini Mental State examination, MMSE) and the cognitive factor of
PANSS were used to assess cognitive function.
Results: No differences were found in the cognitive proﬁle of patients with schizophrenia and mood disorder.
Among patients with schizophrenia, poor verbal performance was associated with the negative or mixed
syndrome (p = 0.004), left or mixed handedness (p = 0.013), greater illness severity (p = 0.030) and lower
GAF scores (p = 0.039). Poor performance on MMSE correlated with higher total PANSS score (p = 0.022)
and was also associated with the negative or mixed syndrome (p = 0.003) and lack of clinical improvement
(p = 0.035).
Conclusion: Patients with the negative or mixed schizophrenia syndromemay suffer more cognitive deﬁcit. Poor
verbal performance among patients with schizophrenia may be associated with left or mixed handedness, more
severe illness and poor functioning.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Background
Cognitive impairment is considered a core feature of schizophrenia
that includes problems in speed of processing, attention/vigilance,
workingmemory, verbal learning, visual learning, reasoning and problem
solving, and social cognition (Green, 2006). Studies have established a
relationship between cognition and functional outcome, consistent across
community and psychosocial functioning, among patients with
schizophrenia (Green, 2006; Heinrichs et al., 2009). These studies have
led to an emerging perspective that while control of symptoms is crucial,
it is not sufﬁcient to ensure a good clinical outcome. Other investigators
have reported a correlation between negative symptoms and functional
capacity (Aubin et al., 2009). The relationship between cognitive impair-
ment, symptom pattern and severity, and patient’s level of functioning, is
however subject to debate (Mohs, 1999).With respect tobipolar disorder,
there is emerging evidence that cognitive impairment may also be a core
feature of bipolar disorder, with cognitive deﬁcits adversely affecting
functional outcomes (Bora et al., 2009; Green, 2006). This raises theal, Aro Abeokuta, Ogun State,
ole).
. This is an open access article underquestion of whether cognitive dysfunction is a feature of psychosis rather
than of schizophrenia as a discrete category.
A search of the literature revealed a paucity of studies on cognitive
functioning among Nigerian patients with schizophrenia. This study
therefore aimed to compare cognitive function among patients with
schizophrenia with mood disorder patients, as well as to investigate
factors associated with poor cognitive function among patients
with schizophrenia.2. Methods
The studywas conducted among patients on admission at the Federal
Neuropsychiatric Hospital, Yaba, Lagos, Nigeria. Consecutively admitted
patients with a diagnosis of schizophrenia [n = 50] or mood disorder
[n = 50] were recruited for the study. Criteria for inclusion were
being above 18 years of age and meeting diagnostic criteria for either
schizophrenia or mood disorder. Criteria for exclusion were having a
history of substance use or signiﬁcant neurological disease (seizure
disorder, head injury, space occupying lesions, dementia), or meeting
diagnostic criteria for both schizophrenia and mood disorder (i.e.
schizoaffective disorder).the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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2.1.1. Sociodemographic questionnaire
A questionnaire was administered to each consenting patient and
control subject concerning basic demographic information including
age, sex, marital status, religious afﬁliation, ethnicity, occupational sta-
tus and highest educational level. Duration of illness and age of onset
of illness were obtained by the history obtained from the patient and
relative. Hospital records were also consulted.
2.1.2. Schedules for Clinical Assessment in Neuropsychiatry, SCAN
Ascertainment of patient diagnosis and cognitive screening was
done using the Schedules for Clinical Assessment in Neuropsychiatry,
SCAN (Wing et al., 1990), for which the lead author has received formal
training. Reliability of all SCAN scales has been found to be moderate to
substantial (Schutzwohl et al., 2007). Diagnosis was based on ICD-10
criteria, for which the SCAN is suited. The SCAN has three components:
the 10th edition of the Present State Examination (PSE 10), the Item
Group Checklist (IGC), and the Clinical History Schedule (CHS). PSE 10
itself is in two parts; Part I includes section 6 (DepressedMood and Ide-
ation) and section 10 (Expansive Mood and Ideation) which are rele-
vant for mood disorder diagnosis. Part II covers psychotic and
cognitive disorders and observed abnormalities of speech, affect and be-
haviour, and is used to interview patients to make a diagnosis of
schizophrenia.
Section 21A (Screening for Cognitive Impairment or Decline) of the
SCAN comprises the Verbal Trails Test and theMini-Mental State Exam-
ination. The verbal trails test is a screening test for front-subcortical dys-
function that may not be picked up by theMMSE (Abe et al., 2004). The
Mini-Mental State Examination (Folstein et al., 1975) is a brief tool for
assessment of cognitive function. It consists of items covering orienta-
tion, registration, attention and calculation, recall, and language. There
is a total possible score of 30.
2.1.3. Positive and Negative Syndrome Scale, PANSS
The Positive and Negative Syndrome Scale, PANSS (Kay et al., 1987)
is a 30-item rating instrument used for dimensional and typological as-
sessment of schizophrenia patients. The 30 items are subdivided into
positive (7 items), negative (7 items) and general psychopathology
(16 items). On the basis of these, patients are classiﬁed as having a pos-
itive, negative or mixed syndrome.
A ﬁve-factor structure of the PANSS, with the items conceptual dis-
organization (P2), difﬁculty in abstract thinking (N5) andpoor attention
(G11) making up a cognitive factor has been described (Rodriguez-
Jimenez et al., 2013). A cognitive factor score on these three items was
obtained for all patients by summing scores on all three items.
2.1.4. Annett Hand Preference Questionnaire, AHPQ
The Annett Hand Preference Questionnaire (Annett, 1970) is a 12-
item scale for assessment of hand preference. Participants are required
to indicatewhether they use their right, left or either hand for six prima-
ry and six non-primary common actions. The primary actions are: writ-
ing, throwing, wielding a racket, striking a match, hammering, and
brushing teeth. The nonprimary actions are: using scissors, threading a
needle, sweepingwith a broom, using a shovel, dealing cards, and open-
ing a jar.
2.1.5. Clinical Global impression, CGI
The CGI scale (Guy, 1976; Haro et al., 2003) evaluates the overall
severity of mental disorders. It consists of three different global
measures designed to rate the effectiveness of a particular treatment:
(i) severity of the illness (assessment of the current severity of
symptoms); (ii) global improvement (comparison of the patient’s
baseline condition to his or her current condition); and (iii) efﬁcacy
index (evaluation of the patient’s improvement from baseline in rela-
tion to treatment side-effects).2.1.6. Global Assessment of Function Scale, GAF
The GAF Scale (American Psychiatric Association, 1994) is an
observer-rated single rating of functioning on a 100 point scale.
2.2. Ethical considerations
Ethical approval was obtained from the Ethical Committee of the
Federal Neuropsychiatric Hospital, Yaba, Lagos, Nigeria. Written in-
formed consent was obtained from all subjects after the study protocol
had been explained to them.
2.3. Study procedure
Study subjects fromeach designatedwardwere recruited as listed in
the nominal roll, which is a record of patients by date of admission and
provisional diagnosis. Thosewith provisional diagnosis of schizophrenia
or mood disorder were approached and after providing informed con-
sent, were interviewed with the Schedules for Clinical Assessment in
Neuropsychiatry (SCAN). Those who met diagnostic criteria for either
group (schizophrenia or mood disorder) were then interviewed with
the socio-demographic questionnaire, the Annett Hand Preference
Questionnaire (AHPQ) and the Global Assessment of Function Scale
(GAF). Patients with schizophreniawere further assessed using the Pos-
itive and Negative Syndrome Scale, PANSS and the Clinical Global im-
pression (CGI). The cognitive screen section of SCAN (comprising
Verbal Trails Test and Mini Mental State examination, MMSE) was also
administered to both groups of patients.
2.4. Data analytic procedures
Results were calculated as frequencies. Group comparisons were
done using chi-squares (categorical variables), t tests, analysis of vari-
ance and bivariate correlation where appropriate (continuous vari-
ables). All tests were 2-tailed, and the level of signiﬁcance was set at
P b 0.05. 95 % Conﬁdence Intervals (95% CI) were calculated where ap-
propriate. In using chi squares, Fisher’s exact test was used in cases
where there were fewer than 5 subjects in a cell.
Statistical analysis was done using the Statistical Package for Social
Sciences, version 15 (SPSS 15).
3. Results
A total of 100 patients (50 with schizophrenia, 50 with mood disor-
der) were approached, all of whom agreed to take part in the study. Pa-
tients with mood disorder included 34 with bipolar affective disorder
and 16 with major depressive disorder.
Themean age of patientswith schizophrenia andmood disorderwas
40.3 years (SD 11.8) and 37.2 years (SD11.9) respectively (t = 1.298,
df = 98, p = 0.197). Mean duration of illness for both groups was
10.2 years (SD 8.2) and 7.1 years (SD 8.7) respectively, with no signiﬁ-
cant difference (t = 1.773, df = 98, p = 0.079). Mean age of onset for
both groups was 30.2 years (SD 11.8) and 30.1(SD 10.4) respectively
(t = 0.027, df = 98, p = 0.979).
Other socio-demographic variables are presented in Table 1. Signiﬁ-
cant differences were found with respect to gender and occupational
status. Table 2 shows a comparison of the performance of patients
with schizophrenia and mood disorder on the domains of cognition.
No signiﬁcant differenceswere found. Among patientswith schizophre-
nia, a comparison of performance on the verbal trails test with selected
clinical variables is shown in Table 3. Poor performance on the verbal
trails test was associated with the negative/mixed schizophrenia syn-
drome, left or mixed handedness, marked/severe illness, and lower
GAF scores.
Lower total scores of schizophrenia patients on the MMSE were
found to correlate with higher PANSS total score (p = 0.022) and the
negative or mixed syndrome (p = 0.013). Patients with paranoid
Table 1
Socio-demographic proﬁle of study subjects.
Schizophrenia
(n = 50)
Mood Disorder
(n = 50)
Differences
Gender
Male 27 (54%) 14 (28%) χ2 = 6.986, df = 1,
Female 23 (46%) 36 (72%) p = 0.014⁎
Marital Status
Married 14 (28%) 17 (34%) χ2 = 0.421, df = 1,
Not Married 36 (72%) 33 (66%) p = 0.666
Religion
Christian 42 (84%) 41 (82%) χ2 = 0.071, df = 1,
Non-Christian 8 (16%) 9 (18%) p = 0.790
Highest Education
Secondary or less 36 (72%) 30 (60%) χ2 = 1.604, df = 1,
Tertiary 14 (28%) 20 (40%) p = 0.291
Employment Status
Employed 10 (20%) 22 (44%) χ2 = 6.618, df = 1,
Unemployed 40 (80%) 28 (56%) p = 0.018⁎
⁎ p b 0.05.
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subtypes (p = 0.041). Higher total MMSE scores also correlated with
clinical improvement (p = 0.035).
To test for differences in performance on the MMSE by educational
level, level of educationwas divided into secondary or less, and tertiary.
A comparison of mean scores showed no signiﬁcant difference in total
MMSE score by educational level (t = −1.622, df = 48, p = 0.111).
No signiﬁcant differenceswere also found in the following sections: ori-
entation (t = −0.818, df = 48, p = 0.417), registration (t = 0.796,
df=48, p=0.430), recall (t=0.830, df=48, p=0.410) and language
(t=−1.867, df = 48, p= 0.068). There was however a signiﬁcant dif-
ference with attention (t=−3.870, df = 48, p b 0.001). Further analy-
sis was done with level of education divided into primary or less,
secondary, and tertiary. This similarly revealed a signiﬁcant difference
only in performance on attention; post hoc Bonferonni analysis showed
the difference to be between primary or less and tertiary (p = 0.001)
and between secondary and tertiary (p = 0.003) but not between pri-
mary or less and secondary (P = 0.193).
The three items comprising the cognitive factor of PANSS were
found to have good internal consistency (Cronbach’s alpha 0.765).Table 2
Group comparison of cognitive function.
Schizophrenia
(n = 50)
Mood Disorder
(n = 50)
Differences
Verbal Trails (%)
Good 19 (38%) 23 (46%) χ2 = 0.657
Poor 31 (62%) 27 (54%) df = 1, p = 0.418
MMSE (Orientation)
Mean (SD) 8.7 (1.7) 9.0 (1.2) t = −1.076, df = 98,
p = 0.285
MMSE (Registration)
Mean (SD) 2.9 (0.5) 2.9 (0.5) t = −0.2, df = 98,
p = 0.84
MMSE (Attention/Calculation)
Mean (SD) 2.3 (1.9) 2.7 (1.7) t = −1.17, df = 98
p = 0.245
MMSE (Recall)
Mean (SD) 1.6 (1.2) 2.0 (1.1) t = −1.85, df = 98
p = 0.067
MMSE (Language)
Mean (SD) 7.2 (2.1) 7.3 (2.1) t = −0.24, df = 1,98
p = 0.810
MMSE (Total)
Mean (SD) 22.4 (2.1) 23.8 (2.1) t = −1.48, df = 98
p = 0.143Scores on each item were added to give a total cognitive factor score.
The total scores correlated with total scores on the MMSE (r =
−0.720, p b 0.001) and the GAF (r =−0.379, p = 0.007).
With respect to socio-demographic variables, there was a negative
correlation between the age of the patient and scores on the cognitive
factor (r = −0.338, p = 0.016). No correlation was however found
with duration of illness or age at onset. Table 4 contains associations be-
tween other socio-demographic and clinical variables of the schizophre-
nia patients with the PANSS cognitive factor scores. Signiﬁcant
associations were foundwith occupational status, type of schizophrenia
presentation, illness severity and treatment response (both assessed by
the CGI) and GAF scores.
4. Discussion
This study aimed to investigate factors associated with cognitive
dysfunction among patients with schizophrenia, on which there is
paucity of data in Sub-Saharan Africa. The study revealed no difference
in the cognitive proﬁle of patients with schizophrenia and mood disor-
der. This agreeswith ameta-analysis of studies comparing patientswith
schizophrenia and mood disorder, which equally found no notable dif-
ference in their cognitive proﬁle (Bora et al., 2009).
However, among patients with schizophrenia, the study revealed
poorer cognitive performance among patients with the negative or
mixed syndrome. This had been earlier reported in Caucasian popu-
lations (Mohs, 1999; Stirling et al., 2003) as well as in Nigeria
(Gureje, 1989).
Patients with greater cognitive deﬁcits were also found to have
greater illness severity and poorer functioning. A correlation between
symptom severity and functional outcomehas been previously reported
(Heinrichs et al., 2009).While Mohs (1999) reported a positive correla-
tion between cognitive deﬁcit and functional impairment but not posi-
tive and negative symptoms, Lin et al. (2013) found clinical (mainly
negative) symptoms to be a mediator of the inﬂuence of neuro-
cognition and social cognition on functional outcome of schizophrenia.
According to Hofer et al. (2005), cognitive dysfunction is the strongest
clinical predictor of poor long term outcome in schizophrenia. They re-
ported associations between severity of cognitive deﬁcits and social
dysfunction, impairments in independent living, occupational
limitations, and disturbances in quality of life. Holthausen et al. (2007)
equally found signiﬁcant differences between patients with and
without cognitive deﬁcits in competitive employment status and voca-
tional functioning.
The ﬁnding of poor verbal performance among patients with a neg-
ative or mixed syndrome would suggest that the neuroanatomical sub-
strate for both is similar, and these features may be useful in predicting
illness severity and functional outcome.While an associationwas found
between performance on the verbal trails test and hand preference, no
such association was found with the cognitive factor of PANSS. This
raises the possibility that there is an association between hand prefer-
ence and verbal performance speciﬁcally, rather than with cognitive
function as a whole. Annett (1998) has proposed a ‘right shift factor’
which may account for a convergence of laterality phenotypes as evi-
dence of decreased cerebral lateralization in schizophrenia.
Prior studies point at a modest correlation between the PANSS cog-
nitive factor and comprehensive neuropsychological assessments, for
instance as reported by Good et al. (2004) among antipsychotic naïve,
ﬁrst episode psychosis patients. However, Bowie et al. (2002) reported
a modest but signiﬁcant relationship between the negative total symp-
tom score of PANSS and the MMSE, as well as between the MMSE and
the Alzheimer’s Disease Assessment Scale—Late Version Cognitive fac-
tor, ADAS-L-Cog, among geriatric schizophrenia patients with severe
impairment. Although no correlation was found in this study between
duration of illness and MMSE scores or performance on the PANSS cog-
nitive factor, the possible mediating effect of this and other variables on
cognitive performance bears further investigation.
Table 3
Clinical variables and performance of schizophrenia patients on verbal trails test.
Good performers (n = 19) Poor performers (n = 31) Difference
Presentation
Paranoid 16 (45.7%) 19 (54.3%) χ2 = 2.947, df = 1,
Others 3 (20%) 12 (80%) p = 0.117
Syndrome type
Positive 15 (57.7%) 11 (42.3%) χ2 = 8.916, df = 1,
Negative/mixed 4 (16.7%) 20 (83.3%) p = 0.004⁎
Hand preference
Right 17 (50%) 17 (50%) χ2 = 6.494, df = 1,
Left/mixed 2 (12.5%) 14 (87.5%) p = 0.013⁎
Illness Severity
Mild/moderate 7 (70%) 3 (30%) χ2 = 5.433, df = 1,
Marked/severe 12 (30%) 28 (70%) p = 0.030⁎
Therapeutic Response
Clinical improvement 15 (46.9%) 17 (53.1%) χ2 = 2.972, df = 1,
No improvement 4 (22.2%) 14 (77.8%) p = 0.130
GAF Score
Mean(SD) 47.1 (SD 10.3) 41.1 (SD 8.0) t = 2.290, df = 48
P = 0.026⁎
⁎ p b 0.05.
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ference of causality. The test battery was also limited to clinical assess-
ments; subsequent studies will need to involve a more comprehensive
neuropsychological battery, as several studies have shown that the do-
mains of cognition which are affected in schizophrenia or psychosis go
beyondwhat is assessed by this study. The longmean duration of illness
of subjects in the current study is also a possible confounder. Future
studiesmay need to compare ﬁrst episode or neuroleptic naïve patients.5. Conclusion
Patients with the negative or mixed schizophrenia syndrome may
suffer more cognitive deﬁcit. Poor verbal performance among patients
with schizophrenia may be associated with left or mixed handedness,
more severe illness and poor functioning. A convergence of these ﬁnd-
ings may be of aetiological importance and may help in selecting pa-
tients for cognitive intervention.Table 4
Association between PANSS cognitive factor and schizophrenia patient variables.
Variables n Mean (SD) t p
Sex
Male 27 8.4 (3.4) 0.768 0.446
Female 23 7.7 (3.1)
Education
Secondary or less 36 8.4 (3.5) 1.079 0.286
Tertiary 14 7.3 (2.5)
Employment Status
Employed 10 6.1 (1.6) −2.240 0.030⁎
Unemployed 40 8.6 (3.4)
Presentation type
Paranoid 35 7.0 (2.6) −4.288 b0.001⁎
Other 15 10.7 (3.1)
Hand Preference
Right 34 7.6 (3.3) −1.484 0.144
Left/mixed 16 9.1 (3.0)
Verbal Trails
Good 19 6.0 (2.5) −4.065 b0.001⁎
Poor 31 9.4 (3.0)
Illness Severity
Mild/Moderate 10 6.2 (2.8) −2.116 0.040⁎
Marked/Severe 40 8.5 (3.2)
Treatment Response
Clinical Improvement 32 7.3 (2.9) −2.430 0.019⁎
No Improvement 18 9.5 (3.4)
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